
Commentary|Videos|December 10, 2024
Dr Matasar on the Use of Odronextamab Monotherapy in R/R DLBCL Following CAR T-Cell Therapy
Author(s)Matthew J. Matasar, MD
Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
Advertisement
Matthew Matasar, MD, chief, Division of Blood Disorders, hematologist, oncologist, professor of medicine, Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, discusses the primary analysis of the phase 1 ELM-1 study (NCT02290951) assessing the efficacy and safety of odronextamab (Ordspono) monotherapy in patients with diffuse large B-cell lymphoma following treatment with CAR T-cell therapy. Matasar and colleagues shared this data during the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































